Buradasınız

Anasayfa » Content

Hodgkin hastalığının standart tedavisinde rekombinant human granülosit koloni stimüle edici faktör kullanımı

Recombinant Human Granulocyte-Colony Stimulating Factor (rh G-CSF) in Standard Chemotherapy of Hodgkin's Disease

Journal Name:

  • İnönü Üniversitesi Tıp Fakültesi Dergisi

Publication Year:

  • 1998

Key Words:

Keywords (Original Language):

Author NameUniversity of AuthorFaculty of Author
Abstract (2. Language): 
Bu çalışmanın amacı Hodgkin hastalığında sitotoksik kemoterapiyi takiben rekombinant human granülosit koloni stimüle edici faktör (rhG-CSF) uygulamasının etkinliğini değerlendirmekti. Yaşları 15 ile 61 (median 44) arasında değişen 19 Hodgkin hastasında toplam 26 rhG-CSF kürü uygulandı. Hastalar 28 günde bir MOPP (Nitrojen Mustart, Vinkristin, Prokarbazine, Prednizolon) aldılar. rhG-CSF subkutan olarak günde 5mJkg 3 uygulandı, bu değerin üstüne çıkanlarda rhG-CSF kesildi. Sonuç prognostik açıdan benzer özelliklere sahip daha önceden aynı kemoterapi ile fakat rhG-GSF'siz olarak tedavi edilmiş 24 kontrol hastası ile karşılaştırıldı. Granülosit sayısının 1000/mm3'ün üstüne çıkma zamanı kontrollere göre anlamlı olarak kısaydı (3±0.72 güne ± düşüktü (%36 ya karşı %64; p<0.05). Fakat dökümante edilen enfeksiyon sıklığında değişiklik yoktu. Tam doz kemoterapi rhG-CSF alanlarda 26/26 (Vol00) uygulanırken kontrol grubunda bu oran yalnızca 18/24 (%75) idi. (p<0.01). Tüm hastalar sitokin tedavisini iyi tolere ettiler. Sonuçlarımız rhG-CSF nin kemoterapi sürerken nötropeni süresini kısaltarak hastaların zamanında ve tam doz kemoterapi almalarında önemli rolu olduğunu göstermektedir. [Turgut Özal Tıp Merkezi Dergisi 1998;5(l):24-29]
Bookmark/Search this post with
Abstract (Original Language): 
The aim of this study was to evaluate the effectiveness of recombinant granulocyte colony stimulating factor (rhG-CSF) administered following cytotoxic chemotherapy in Hodgkin's disease. Total number of 26 courses of rhG-CSF were applied in 19 patients with Hodgkin's disease aged 15 to 61 (median 44) years. They received MOPP (Nitrogen Mustard, Vincritine, Procarbazine, Prednisone) chemotherapy every 28 days. rhG-CSF was given at a dose of 5ji/kg daily and subcutaneously from day 2n to 6th day 8th to 20th unless the neutrophil count exceeded 10.000/mm3, in which case rhG-CSF discontinued. The outcome was compared with 24 prognostically similar control patients treated with the same chemotherapy without rhG-CSF. Recovery of granulocyte counts above 1000/mm was significantly faster in the rhG-CSF treated group (3±0.72 days vs 7±0.81 days; p<0.001). The incidence of febrile neutropenia and empiric parenteral antibiotic use were lower in study patients (%36 vs %64 ; p<0.05). But there was no reduction in the incidence of documented infections. Full doses of chemotherapy could be given on time to 26/26 (%100) rhG-CSF patients but to only 18/24 (%75) controls (p<0.01). All patients tolerated cytokine treatment well. Our results showed that rhG-CSF has an important role in decreasing period of neutropenia maintaining chemotherapy schedule and allowing patients to receive full doses of chemotherapy on time. [Journal of Turgut Özal Medical Center 1998;5(1):24-
FULL TEXT (PDF): 
PDF icon arastirmax-hodgkin-hastaliginin-standart-tedavisinde-rekombinant-human-granulosit-koloni-stimule-edici-faktor-kullanimi.pdf
  • 1
24-29
  • Turkish

REFERENCES

References: 

1. Eyre HJ. The lymphomas, in Lee RG, Bithel CT, Athens JW, Lukens JN ed(s): Wintrobe's Clinical Hematology. 9th ed, Philadelphia . Lea & Febiger,1993, 2054-81.
2. Straus DJ. Strategies in the treatment of Hodgkin's disease. Semin Oncol 1986;13:26-34.
3. Pizzo PA. Granulocytopenia and cancer therapy. Past problems, current solutions, future challenges. Cancer 1984 ;.
54 : 2649-61.
4.
association. Am J Med 1986; 81 (suppl 1 A): 11-26.
5. Bodey GP, Buckley M, Sathe YS, Freireich EJ. Quantitative relationships beween circulating leucocytes and infection in patient with acute leukemia. Ann Intern Med 1966; 64: 328¬40.
6. Steward WP, Scarffe JH. Clinical trials with haematopoietic growth factors. Progr Growt Factor Res 1989; 1: 1-12.
7. Neidhart JA. Hematopoietic cytokines: Current use in cancer therapy. Cancer 1993; 72: 3381-6.
8. Groopman JE, Molina JM, Scadden DT. Hematopoietic growth factors. Biology and clinical applications. N Eng J Med 1989;
321 : 1449-59.
9. Metcalf D. The colony stimulating factors. Discovery, development and clinical applications. Cancer 1990; 65 :2185-
94.
10. Bradley TR, Metcalf D. The growth of mouse bone marrow cells in vitro. Austr J Exp Biol Med Sci 1966; 44: 287-300.
11. Pluznic DH, Sachs L. The induction of clones of normal mast cell by a substance from conditioned medium. Exp. Cell Res 1966; 43 : 553-63.
12. Glaspy JA Golde DW. Clinical applications of myeloid growth factors. Blood 1989; 74: 1303-7.
13.
Endojen
kolon
i stimüle edici faktörlerin (CSF) klinik kullanımı. Türk Onkoloji Dergisi 1991;6:1205-10.
14. Lieschke GJ, Burgess AW. Granulocyte colony-stimulating factor and Granulocyte-Macrophage colony-stimulating factor. N Engl J Med 1992; 327: 28-35.
15. Davis I, Morstyn G. Granulocyte colony-stimulating factor: biology and clinical application, in Syman M, Quesenberry PJ, Morstyn ed(s) Haematopoietic growth factors. Marciesfield:
Gardner-Caldwell, 1992; 67-77.
16. Metcalfe D. The colony stimulating factors. Discovery, development and clinical applications. Cancer 1990; 65 :2185-
94.
17. Neidhart JA. Hematopoietic colony stimulating factors. Uses in combination with standard chemotherapeutic regimen and in suppor of dose intensification. Cancer 1992; 70 : 913-20.
18. Crawford J, Ozer H, Stoller R,. Reduction by granulocyte colony-stimulating factor of fever and neutropenia induced by chemotherapy in patients with small-cell lung cancer. N Engl J Med 1991; 325: 164-70.
19. Sheridan WP, Beglen CG, Juttner CA, et al. Effect of
peripheral-blood progenitor cells mobilised by filgrastim (G-CSF) on platelet recoveryafter high-dose chemotherapy. Lancet 1992; 339: 640-4.
20. Ohno R, Tomonaga M, Kobayashi T. Effect of Granulocyte colony stimulating factor after intensive induction therapy in relapsed or refractory acute leukemia. N Engl J Med 1990;
323: 871-7.
21. Petengel R, Gurney H, Radford JA. Granulocyte colony-stimulating factor to prevent dose-limiting neutropenia in non Hodgkin's lymphoma: A randomized controlled trial. Blood
1992; 80: 1430-6.
22. Silvestri F, Virgolini L, Velisig M, et al. Granulocyte colony-stimulating factor (G-CSF) allows delivery of effective dose of CHOP and CVP regimen in non-Hodgkin's lymphoma (NHL). (Abstract) Br J Haematol 1994; 87(suppl 1): 161.
23. Taylor KMcD, Jagannath S, Spitzer G, et al. Recombinant human Granulocyte-colony stimulating factor hastens granulocyte recovery after high-dose hemotherapy and autologous bone marrow transplantation in Hodgkin's disease. J Clin Oncol 1989; 7: 1791-9.
24. Hovgaard DJ, Nissen NI. Effect of recombinant human granulocyte-macrophage colony stimulating factor in patients with Hodgkin' s Disease: A Phase I / II study. J Clin Oncol 1992; 10 : 390-7.
25. Ricardi A, Gobbi P, Danova M, et al. MOPP / ABV / CAD
chemotherapy with and without recombinant human granulocyte-macrophage colony stimulating factor in untreated, unfavorable prognosis Hodgkin's disease.
Haematologica 1993; 78: 44-8.
26.
yayın
no
: 94, 1994; .155-7, 140-3.
27. Scherrer R, Geissler K, Kyrle PA. Granulocyte colony-stimulating factor (G-CSF) as an adjunct to induction chemotherapy of adult acute lymphoblastic leukemia (ALL).
Ann Hematol 1993; 66 : 283-9.
28. Ottman GO, Ganser A, Freund M, et al. Simultaneous administration of granulocyte colony-stimulating factor (Filgrastim) and induction chemotherapy in acute lymphoblastic leukemia. Ann Hematol 1993; 67: 161-7.
28
Turgut ÖzalTıp Merkezi Dergfci5(l):1998
et al.
rh G-CSF in standard chemotherapy of Hodgkin's disease
29. Valent P, Sillber Ch, Geissler K,. Combination treatment of acute myeloblastic leukemia with rhGM-CSF and standard induction chemotherapy Cancer Invest 1993; 11(2) : 229-34.
30. Lindeman A, Herrman O, Oster W. Hematologic effects of recombinant human granulocyte colony-stimulating factor in
patient with malignancy. Blood 1989; 74 : 2644-51.
31. Morstyn G, Sauza LM, Keech J. Effect of Granulocyte colony stimulating factor on neutropenia induced by cytotoxic
chemotherapy. Lancet 1988; 8587 : 667-71.
32. Gulati SC, Bennet CL. Granulocyte-macrophage-colony stimulating factor (GM-CSF) as adjunct therapy in relapsed
Hodgkin disease. Ann Int Med 1992;116 : 177-82.
33. Brandt SJ, Petters WP, Atwater SK,. Effect of recombinant human Granulocyte-macrophage colony stimulating factor on hematopoietic reconstitution after high-dose chemotherapy and autologous bone marrow transplantation. N Engl J Med 1988; 318 : 869-76.
34. Link H, Boogaerts MA. Carella AM.. A controlled trial of
recombinant human granulocyte-macrophage colony-stimulating factor after total bodyirradiation, high-dose chemotherapy, and autologous bone marrowtransplantation for
acute lymphoblastic leukemia or malignant lymphoma. Blood
1992; 80:2188-95.
35. Nicola NA. Hemopoietic cell growth factors and their
receptors. Ann Rev Biochem 1989; 58 : 45-77.
36. Gerhartz HH, Engelhard M, Meusers P. Randomized, double-blind, plasebo controlled, phase III study of recombinant human granulocyte-macrophage colony-stimulating factor as adjunct to induction treatment of high-grade malignant Non-
Hodgkin's lymphomas. Blood 1993; 82: 2329-39.
37. Watari K, Asona S, Shirafuji N, et al . Serum granulocyte colony-stimulating factor levels in healty volunteers and patients with various disorders as estimated by enzyme immunoassay. Blood 1989; 73 : 117-22.

Thank you for copying data from http://www.arastirmax.com